Hepatitis C News and Research

Latest Hepatitis C News and Research

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Widely used biomarkers are not optimal in early detection of liver cancer, the third most common cause of cancer-related death worldwide, according to a new study published in this month's Gastroenterology.

26 Feb 2010

Surge in volunteers without overall coordination can make devastating situation worse instead of better

A surge in volunteers following a major disaster can overwhelm a response system, and without overall coordination, can actually make a situation worse instead of better. The outpouring of medical volunteers who responded to the devastating earthquake that rocked Haiti in January provides a roadmap for health care providers during future disasters, say the authors of a New England Journal of Medicine "Perspectives" piece that will be published online February 24.

26 Feb 2010

Combining DCP and AFP biomarkers may improve early detection of liver cancer

While biomarkers are needed to complement ultrasound in the early detection of hepatocellular carcinoma (HCC; liver cancer), neither des-gamma-carboxy prothrombin (DCP) nor the most widely used biomarker, alpha fetoprotein (AFP), is optimal, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

26 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from an ongoing Phase II study demonstrating that 73% of hepatitis C patients treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin (SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Lack of knowledge and awareness impeding efforts to control HBV and HCV

A recent report by the Institute of Medicine (IOM) confirmed that 3.5 to 5.3 million people (1-2 % of the U.S. population) have chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Despite efforts by federal, state and local government agencies to control and prevent these diseases, they remain a serious public health concern. The major factor impeding efforts to control HBV and HCV is lack of knowledge and awareness among health care providers, social service professionals, members of the public, and policy-makers.

24 Feb 2010

Mouse study provides new way to test novel therapies for liver infections

How do you study-and try to cure in the laboratory-an infection that only humans can get? A team led by Salk Institute researchers does it by generating a mouse with an almost completely human liver.

24 Feb 2010

NanoViricides files quarterly report with Securities and Exchange Commission

NanoViricides, Inc. has filed its quarterly report with the Securities and Exchange Commission yesterday in a timely fashion.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that the ASTUTE Study (AST-120 Used to Treat Hepatic Encephalopathy) has completed enrollment for its Phase 2B study ahead of schedule, with data expected mid 2010.

24 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Haitian President says up to 300,000 people could have died in quake

The major earthquake in January in Haiti could have killed as many as 300,000 people, an estimate that includes bodies buried in the rubble, Haitian President Rene Preval said on Sunday at a meeting of Latin American and Caribbean leaders in Mexico, Reuters reports.

23 Feb 2010

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free.

21 Feb 2010

AltraVax acquires vaccine development technology package from Maxygen

AltraVax, Inc., a new, privately-held biopharmaceutical company, has acquired a vaccine development technology package from Maxygen, Inc. that gives AltraVax an exclusive license to develop vaccines for infectious diseases and is targeting influenza, a treatment for hepatitis B and HIV.

18 Feb 2010

Medivir reports 2009 financial results

Medivir had a very satisfactory 2009. Our cold sore product secured market approval in the US and Europe and is well positioned for launch. This will take place under the XerclearTM trademark in Europe, and under the XereseTM trademark in the US during 2010.

18 Feb 2010

Utah tries to improve state health insurance exhange; Mich. plans for doctor shortage

The Salt Lake Tribune: "State health reform got a boost Tuesday with House passage of a fix-it bill to improve the Utah Health Exchange, an online tool for purchasing health insurance. Pitched as a free-market approach to lowering costs for small businesses, the exchange has had limited success. Only 400 people are receiving health insurance in its experimental first stage. And some of its 66 plans are up to 130 percent more expensive than what some companies were already paying. That's because insurers are calculating premiums differently 'inside' and 'outside' the exchange, said House Speaker Dave Clark" (Stewart, 2/16).

17 Feb 2010

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Pharmasset, Inc. announced today the complete enrollment by Roche of the 12 week RG7128 Phase 2b study (PROPEL) of approximately 400 treatment-naive patients with hepatitis C virus (HCV) genotypes 1 and 4. The study remains blinded to Roche and Pharmasset.

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

Biota Holdings reports total revenue of $61.7M for half-year of 2009

Biota Holdings Limited today announced a half year net profit after tax of $33.5 million, (1H F09: $7.2m). Profit before tax was $41.4 million (1H F09: $10.1m) benefiting significantly from an increase in Relenza royalties.

16 Feb 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Widely used biomarkers in early detection of liver cancer are not ideal: Study

Surge in volunteers without overall coordination can make devastating situation worse instead of better

Combining DCP and AFP biomarkers may improve early detection of liver cancer

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Lack of knowledge and awareness impeding efforts to control HBV and HCV

Mouse study provides new way to test novel therapies for liver infections

NanoViricides files quarterly report with Securities and Exchange Commission

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Haitian President says up to 300,000 people could have died in quake

Two genetic alterations linked to benign enzyme condition keep hepatitis C patients anemia-free

AltraVax acquires vaccine development technology package from Maxygen

Medivir reports 2009 financial results

Utah tries to improve state health insurance exhange; Mich. plans for doctor shortage

Roche completes enrollment in RG7128 Phase 2b PROPEL study

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

Biota Holdings reports total revenue of $61.7M for half-year of 2009

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in